Toggle main menu
There will be two half-day sessions. Further details to be announced soon.
Chair Mat Donati Joint Vice Chairs Catherine Moore and Stephen Winchester Secretary Husam Osman Treasurer Sowsan Atabani Scientific Affairs and Research Secretary Will Irving Meetings Secretary Stephen Winchester Website and Communications Secretary Mark Zuckerman Audit and Guidelines Secretary Alison Watt Clinical Scientists Representative Kelly Bicknell Biomedical Scientists Representative Jayne Harwood Medical Virology Representative Sophie Gillett Commercial Companies Representative Karen Jordan Coffey CVN Administrative Assistant Maggie Hopper
The UK CVN membership has key skills and experience to provide advice on the delivery of the UK COVID-19 pandemic response. In recognition of this, and in order to provide a representative view, the UK CVN executive agreed to form an advisory group comprising members across all regions and countries of the UK, and from the Republic of Ireland. At formation, the CVNAG will only consider topics related to SARS-CoV-2 and COVID-19. In due course, the group may widen the remit to cover other virological areas.
July 06, 2020
The authors selected pairs of highly-potent individual antibodies that could simultaneously bind the receptor-binding domain of the spike protein.
July 06, 2020
Some novel spike mutants did rapidly appear following in vitro passaging in the presence of the antibodies individually, leading to a loss of neutralisation
July 03, 2020
Neutralising antibodies could be used for prophylaxis, and potentially therapy, of COVID-19
July 03, 2020
These antibodies are promising therapeutic candidates and provide evidence for vaccine design
July 02, 2020
Antibodies may be used for therapeutic interventions, and also suggest that a pan-sarbecovirus vaccine may be possible.
July 02, 2020
Patients with COVID-19 can develop asymptomatic lung infection with viral shedding and those with evidence of pneumonia on imaging tend to have a higher antibody response.
Login or register to start contributing to our message boards
Disclaimer
The information contained in this website is provided ‘as is’ without warranty of any kind. The entire risk as to the results and the performance of the information is assumed by the user, and in no event shall The UK Clinical Virology Network be liable for any consequential, incidental or direct damages suffered in the course of using the information on this website. Use of the information contained on this website are governed by their respective license agreements and may contain restrictions on use.
The UK Clinical Virology Network does not endorse or recommend any commercial products, processes, or services.
January 17, 2019
November 14, 2018
July 24, 2018
May 25, 2017
May 25, 2017
January 09, 2017